外周血中微RNA-16和微RNA-124表达水平对抑郁症患者治疗效果的影响  

Effect of microRNA-16 and microRNA-124 in peripheral blood on clinical efficacy in patients with depression

作　　者：邵秋静 冀紫阳 董娇[1] 王长虹[1] SHAO Qiujing;JI Ziyang;DONG Jiao;WANG Changhong(Department of Psychiatry,the Second Affiliated Hospital of Xinxiang Medical University,Xinxiang 453002,Henan Province,China)

机构地区：[1]新乡医学院第二附属医院精神科,河南新乡453002

出　　处：《新乡医学院学报》2022年第4期318-322,329,共6页Journal of Xinxiang Medical University

基　　金：河南省精神心理疾病临床医学研究中心开放课题(编号:2020-zxkfkt-004)。

摘　　要：目的探讨外周血中微RNA(miR)-16、miR-124表达水平对抑郁症患者治疗效果的影响。方法选择2020年5月至2021年3月新乡医学院第二附属医院收治的60例抑郁症患者为研究对象。患者均接受米氮平片口服治疗,起始剂量为15 mg·d^(-1),服用2周后增加至30 mg·d^(-1),并维持此剂量服用;若服用2周后治疗效果不明显,可将米氮平片增加至45 mg·d^(-1),或调整为联合口服艾司西酞普兰,艾司西酞普兰起始剂量为每次10 mg·d^(-1);治疗周期为3个月。治疗3个月后,采用汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)评估所有患者临床疗效,并根据临床疗效将患者分为疗效不佳组(n=19)和疗效良好组(n=41)。治疗前,采集患者空腹静脉血3 mL,采用实时荧光聚合酶链式反应法检测患者外周血中miR-16、miR-124相对表达量。采用logistic回归分析外周血中miR-16、miR-124表达与抑郁症患者临床疗效的关系。绘制受试者工作曲线,并计算曲线下面积(AUC),分析外周血中miR-16、miR-124表达预测抑郁症患者临床疗效的价值。结果疗效良好组患者外周血中miR-16相对表达量显著高于疗效不佳组,miR-124相对表达量显著低于疗效不佳组(P<0.05)。Logistic回归分析结果显示,miR-16是抑郁症患者临床疗效的保护因子(OR<1,P<0.05),miR-124是抑郁症患者临床疗效的危险因子(OR>1,P<0.05)。抑郁症患者外周血中miR-16、miR-124相对表达量单独及联合检测预测抑郁症患者临床疗效的AUC分别为0.843、0.849、0.944。外周血中miR-16和miR-124相对表达量单独及联合检测预测抑郁症患者临床疗效的AUC、敏感度比较差异无统计学意义(P>0.05)。miR-16、miR-124相对表达量联合检测预测抑郁症患者临床疗效的特异度显著高于miR-16相对表达量单独检测,显著低于miR-124相对表达量单独检测(P<0.05)。结论抑郁症患者接受艾司西酞普兰、米氮平治疗的临床疗效欠佳可能受外周Objective To investigate the effect of microRNA(miR)-16 and miR-124 expressions in peripheral blood on clinical efficacy in patients with depression.Methods A total of 60 depression patients admitted to the Second Affiliated Hospital of Xinxiang Medical University from May 2020 to March 2021 were selected as the research subjects.All patients received oral mirtazapine tablet,the initial dose was 15 mg·d^(-1),which was increased to 30 mg·d^(-1) after two weeks of taking,and the dose was maintained;if the treatment effect was not obvious after two weeks of taking,mirtazapine tablet could be increased to 45 mg·d^(-1),or adjusted to be combined with oral escitalopram,the starting dose of escitalopram was 10 mg·d^(-1);the treatment period was three months.After three months of treatment,Hamilton anxiety scale(HAMA)and Hamilton depression scale(HAMD)were used to evaluate the clinical efficacy of all patients,and patients were divided into poor efficacy group(n=19)and good efficacy group(n=41)according to clinical efficacy.Before treatment,3 mL of fasting venous blood was collected from patients,and the relative expression levels of miR-16 and miR-124 in peripheral blood of patients were detected by real-time fluorescence polymerase chain reaction method.The relationship between the expression of miR-16 and miR-124 in peripheral blood and the clinical efficacy of patients with depression was analyzed by logistic regression.The value of the miR-16 and miR-124 expression in peripheral blood in predicting clinical efficacy in patients in the depression was analyzed by receiver operator characteristic,and the area under curve(AUC)was calculated.Results The relative expression level of miR-16 in peripheral blood of patients in the good efficacy group was significantly higher than that in the poor efficacy group,and the relative expression level of miR-124 was significantly lower than that in the poor efficacy group(P<0.05).Logistic regression analysis showed that miR-16 was the protective factor for clinical efficacy in

关 键 词：抑郁症 微RNA-16 微RNA-124 临床疗效 

分 类 号：R749[医药卫生—神经病学与精神病学]